Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedUpgrade to v3.2.0 with a government-operating-status notice; the previous v3.1.0 reference has been removed.SummaryDifference3%
- Check20 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedPage now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' navigation element was removed.SummaryDifference0.2%
- Check41 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.2%
- Check48 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location details, while key drug information related to pembrolizumab has been removed.SummaryDifference4%
- Check63 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.